Restoring Dystrophin via Exon Skipping Strategies AOC 1044 – Mark Stahl, MD (Avidity Biosciences) BMN 351 – Dave Jacoby MD, PhD (BioMarin Pharmaceutical Inc.) DYNE-251 – Ash Dugar, PhD, MBA (Dyne Therapeutics) ED051 – Michelle Mellion, MD (PepGen, Inc.) ENTR-601-44 – Nerissa Kreher, MD, MBA (Entrada Therapeutics) SRP-5051 – Teji Singh, MD (Sarepta Therapeutics) WVE-N531 – Mike Panzara, MD, MPH (Wave Life Sciences) 2022 PPMD Annual Conference,Conferences & Meetings 2 years ago You may also like 7:11 Epirium Bio 4 years ago Conferences & Meetings,In the Pipeline: Downstream Targets 18:36 Sarepta Therapeutics (RNA Targeted Therapies) 4 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 11:46 NS Pharma 4 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 11:20 PTC Therapeutics (Ataluren) 4 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 15:10 Daiichi-Sankyo 4 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 20:43 ReveraGen BioPharma 4 years ago Conferences & Meetings,In the Pipeline: Reducing Inflammation 12:20 Catabasis 4 years ago Conferences & Meetings,In the Pipeline: Reducing Inflammation 11:23 Antisense Therapeutics 4 years ago Conferences & Meetings,In the Pipeline: Reducing Inflammation «1…1920212223…25»Page 21 of 25
by: Parent Project Muscular Dystrophy
